Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Alnylam Pharmaceuticals Inc Conference Call to Discuss Strategic Financing Collaboration with Blackstone Transcript

Apr 13, 2020 / 12:30PM GMT
Release Date Price: $119.01 (+2.26%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss strategic financing collaboration with Blackstone. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request.

I would now like to turn the call over to the company.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - VP of IR & Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maraganore, Chief Executive Officer; Yvonne Greenstreet, Chief Operating Officer; and Jeff Poulton, Chief Financial Officer. Barry Greene, President; and Akshay Vaishnaw, President of R&D, are also on the line and available for Q&A.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.

During today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot